Ingredion Incorporated (NYSE: INGR) has appointed Diego Reynoso as chief financial officer, effective October 1, 2026. Reynoso will join the executive leadership team and report directly to Jim Zallie, chairman, president and chief executive officer.

Reynoso arrives from Boston Beer Company, where he served as CFO overseeing finance, investor relations, IT, M&A and enterprise strategy. His background includes leadership roles at Tyson Foods, Constellation Brands, Beam Suntory, Danone and Procter & Gamble.

Strategic Focus

In his new role, Reynoso will lead the finance organization while advancing Ingredion’s growth strategy. Key responsibilities include driving enterprise productivity initiatives, disciplined capital allocation and integration execution as part of the company’s transformation into a leading global ingredient solutions provider.

Zallie highlighted Reynoso’s experience in major integration and portfolio transformations across the food and beverage industry. He noted that Reynoso’s focus on profitable growth and shareholder value creation would be critical for advancing Ingredion’s long-term strategy.

Executive Perspective

Reynoso stated that Ingredion possesses a clear strategy and strong culture with significant opportunities to accelerate growth. He emphasized a commitment to enhancing productivity through disciplined execution, innovation and continued value creation for customers and shareholders.

About Ingredion

Headquartered in Westchester, Illinois, Ingredion serves customers in more than 120 countries. The company reported $7.2 billion in annual net sales for 2025. It employs more than 11,000 people and operates innovation centers globally to develop plant-based ingredient solutions for food, beverage, animal nutrition, brewing and industrial markets.

Tate & Lyle PLC shareholders have accepted Ingredion Incorporated’s recommended all-cash offer to acquire the entire issued and to be issued share capital of the British ingredient solutions provider. The acceptance, confirmed on July 28, 2026, marks a critical milestone in the transaction originally announced on June 8, 2026. This approval paves the way for the creation of a combined global leader in food, beverage, pharmaceutical, and personal care ingredients, carrying significant strategic weight for enhanced innovation capabilities and market position.

The offer price stands at 595 pence per share in an all-cash structure. Jim Zallie, chairman, president and CEO of Ingredion, stated that the shareholder vote reflects confidence in the combined entity’s ability to drive future growth. "Today marks an important milestone toward establishing a global leader in ingredient solutions that will help create the future of food," Zallie said. The Board of Directors of Tate & Lyle had previously recommended the offer to its shareholders, facilitating the acceptance process.

Financial Synergies and Value Creation

Ingredion projects substantial financial benefits from the merger, centered on operational efficiencies and earnings accretion. The company expects to achieve run-rate net cost synergies of approximately $130 million, with full realization targeted by the end of 2030. These synergies are expected to drive adjusted EPS accretion for Ingredion shareholders in the first year following completion. Furthermore, the combined group anticipates an enhanced long-term growth profile and improved earnings potential, leveraging complementary capabilities in formulation and product development.

Regulatory Path and Integration

Despite shareholder approval, the transaction remains subject to regulatory review and clearance as outlined in the scheme document. Ingredion confirmed that it continues to operate as a separate business from Tate & Lyle until the deal closes. Regulatory approvals are ongoing, with management focused on securing necessary clearances efficiently. The company has indicated that closing is expected in the second half of 2027, assuming all conditions are satisfied.

Zallie emphasized the strategic rationale behind the merger, noting that combining Ingredion’s and Tate & Lyle’s capabilities will strengthen their ability to solve complex formulation challenges. "We will strengthen our ability to help customers solve complex formulation challenges with an expanded innovation engine to accelerate product development," he added. The integration aims to deliver healthier, affordable, and high-quality food products to consumers globally.

What the Numbers Show

The commitment to $130 million in net cost synergies by 2030 suggests a disciplined approach to post-merger integration, focusing on operational efficiency rather than immediate revenue scaling. With Ingredion reporting 2025 annual net sales of approximately $7.2 billion, the addition of Tate & Lyle represents a significant expansion of its addressable market. The accretive nature of the deal in the first year indicates that the projected synergies are expected to outweigh integration costs quickly, providing early value to shareholders while the longer-term growth profile matures.